Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

275 questions · 306 findings · 35 reviews · Oral Health

No studies found 48 · 15.7%GRADE not reported 177 · 57.8%Very low 63 · 20.6%Low 15 · 4.9%Moderate 3 · 1%High 0 · 0%

Dietary supplements (hypericum perforatum / St John's Wort) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months) · hypericum perforatum
    Hypericum perforatum extract (Sardella 2008, the only low-risk-of-bias study) contributes to the dietary supplements short-term symptom-relief comparison (insufficient/contradictory); no separate estimate reported.
    1 study · 43 participants
    GRADE not reported

Physical barriers (tongue protector + reinforced self-control instruction) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether physical barriers (tongue protector + reinforced self-control… changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Colchicine (0.5 mg per day for 3 months) vs prednisolone

Pain at completion of treatment · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Colchicine (0.5 mg per day for 3 months) showed no clear difference in pain at completion of treatment compared with prednisolone (5 mg per day for 3 months); GRADE not reported.

1 finding from 1 review

Light vibrational forces (LVF) vs Conventional orthodontic appliance treatment

Discomfort/pain · Adolescents and adults with malocclusion undergoing orthodontic treatment with fixed or removable appliances

Light vibrational forces (LVF) showed no clear difference in patient perception of pain and discomfort (VAS 0 to 100 mm),… compared with conventional orthodontic appliance treatment (placebo or no adjunct) (low certainty).

1 finding from 1 review

Any surgical or non-surgical technique or material used for the treatment of post-extraction bleeding vs Placebo, no treatment, or another active antifungal intervention

Discomfort associated with the procedure · People of any age and either gender with post-extraction bleeding, regardless of type of teeth (anterior or posterior, mandibular or…

The review found no eligible studies for this question.

1 finding from 1 review

Vitamin B12 (sublingual, 1000 mcg daily for 6 months) vs placebo

Pain score · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Vitamin B12 (sublingual, 1000 mcg daily for 6 months) led to lower pain score compared with placebo; GRADE not reported.

1 finding from 1 review

Aciclovir (oral or intravenous) for treatment vs placebo

Relief of pain · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
1 finding from 1 review

Subantimicrobial dose doxycycline (20 mg twice daily for 90 days) vs placebo

Mean VAS pain per day · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Subantimicrobial dose doxycycline (20 mg twice daily for 90 days) showed no clear difference in mean VAS pain per day compared with placebo; GRADE not reported.

1 finding from 1 review

Leukotriene receptor antagonist vs placebo

Pain intensity (0‐10cm visual analogue scale) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Montelukast (leukotriene receptor antagonist; 10 mg daily for 1… led to lower pain (visual analogue scale) compared with placebo; GRADE not reported.

1 finding from 1 review

Pentoxifylline vs placebo

Pain, number of ulcers, ulcer-free days and ulcer size · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
  • Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
    60 days (plus 60-day follow-up)
    A single trial at high risk of bias compared pentoxifylline 400 mg three times daily (n=14) with placebo (n=12). No statistically significant differences were reported for pain, number of ulcers and ulcer-free days at…
    1 study · 26 participants
    GRADE not reported

Tetracycline suspension (250 mg, held in mouth 2 minutes then swallowed, four times daily for 5 days) vs placebo

Adjusted maximum ulcer size and adjusted maximum pain · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review

Dietary supplements (alpha lipoic acid +/- vitamins/lycopene/green tea; hypericum; Catuama; lycopene) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months)
    SoF5 Dietary supplements vs placebo. Symptom relief short-term: insufficient or contradictory evidence regarding benefit of any evaluated dietary supplement; 628 participants (12 RCTs); very low. Subgroups: ALA without…
    12 studies · 628 participants
    Very low

Topical treatments (benzydamine hydrochloride oral rinse) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months) · benzydamine hydrochloride
    SoF9 Topical treatments vs placebo. Symptom relief short-term: insufficient or contradictory evidence regarding benefit of any evaluated topical treatment; 150 participants (4 RCTs); very low. Subgroups: benzydamine (1…
    4 studies · 150 participants
    Very low

Benzodiazepines (topical clonazepam) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (topical clonazepam) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

2 findings from 1 review

Anticonvulsants (gabapentin 300 mg/day, +/- alpha lipoic acid) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether anticonvulsants (gabapentin 300 mg/day, +/- alpha lipoic acid) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Low‐level laser therapy vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether electromagnetic radiation (low-level laser therapy) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Benzodiazepines (systemic clonazepam 0.5 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (systemic clonazepam 0.5 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Cholinergics (bethanechol 15 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether cholinergics (bethanechol 15 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Psychological therapies (cognitive therapy) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether psychological therapies (cognitive therapy) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Topical treatments (capsaicin oral rinse) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
2 findings from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months) · capsaicin oral rinse
    Capsaicin oral rinse (Marino 2010; Silvestre 2012) contributes to the topical treatments short-term symptom-relief comparison (insufficient/contradictory). Silvestre 2012 data not presented due to 23% first-phase…
    1 study
    GRADE not reported
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    long-term (>3 to 6 months) · capsaicin oral rinse
    MD -2.60 [-5.11, -0.09]
    1 study · 18 participants
    Very low